Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children with Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Trial Identifier: D1346C00015
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme Corp.
Start Date: July 2021
Primary Completion Date: April 2022
Study Completion Date: January 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation
Spanish Translation
Polish Translation
Russian Translation

Trial Locations

Country Location
ES Barcelona, ES, 08950
ES Madrid, ES, 28009
PL Bydgoszcz, PL, 85-094
PL Gdańsk, PL, 80-952
PL Warszawa, PL, 02-091
RU Moscow, RU, 119620
RU Moscow, RU, 125412
US, MN Rochester, MN, US, 55905
US, OH Akron, OH, US, 44308